Last reviewed · How we verify
NCT05067348: tMG
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
Recruiting now
Phase 2
Last updated 1 May 2025
What this trial tests
Phase 2 trial testing Tocilizumab Injectable Product in Myasthenia Gravis, Generalized in 64 participants. Currently enrolling.
Timeline
21 July 2022
Primary endpoint
31 December 2025
31 December 2025
30 March 2026
Quick facts
| Lead sponsor | Tang-Du Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 64 |
| Start date | 21 July 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 30 March 2026 |
| Sites | 6 locations across China |
Drugs / interventions tested
- Tocilizumab Injectable Product — full drug profile →
Conditions studied
- Myasthenia Gravis, Generalized — all drugs for Myasthenia Gravis, Generalized →
Sponsor
Tang-Du Hospital
Who can join
Adults 18 to 80, any sex, with Myasthenia Gravis, Generalized. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel Immunotherapies for Myasthenia Gravis.
Nair SS, Jacob S. · · 2023 · cited 38× · PMID 37038596 · DOI 10.2147/itt.s377056 -
Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment.
Gilhus NE, Andersen H, Andersen LK, Boldingh M, et al · · 2024 · cited 33× · PMID 38321574 · DOI 10.1111/ene.16229 -
Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
Vakrakou AG, Karachaliou E, Chroni E, Zouvelou V, et al · · 2023 · cited 33× · PMID 37564637 · DOI 10.3389/fimmu.2023.1212757 -
New and emerging treatments for myasthenia gravis.
DeHart-McCoyle M, Patel S, Du X. · · 2023 · cited 25× · PMID 37560511 · DOI 10.1136/bmjmed-2022-000241 -
New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies.
Sánchez-Tejerina D, Sotoca J, Llaurado A, López-Diego V, et al · · 2022 · cited 15× · PMID 36362622 · DOI 10.3390/jcm11216394 -
Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis.
Jia D, Zhang F, Li H, Shen Y, et al · · 2024 · cited 13× · PMID 37450932 · DOI 10.14336/ad.2023.0528 -
Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.
Ruan Z, Tang Y, Gao T, Li C, et al · · 2024 · cited 9× · PMID 38894580 · DOI 10.1111/cns.14793 -
Treating myasthenia gravis beyond the eye clinic.
Jacob S. · · 2024 · cited 9× · PMID 38789789 · DOI 10.1038/s41433-024-03133-x
Verify or expand the search:
- PubMed search for NCT05067348
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tocilizumab Injectable Product
Trials testing the same drug.
- NCT04616235 — Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade · NA · completed
Other recruiting trials for Myasthenia Gravis, Generalized
Currently open trials in the same condition.
- NCT07072988 — Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC E · Phase 4 · recruiting
- NCT06909253 — Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis · recruiting
- NCT06455709 — Markers of Favorable Response to Complement Inhibitors Therapy · recruiting
- NCT04806620 — Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research · recruiting
- NCT05868837 — Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) · Phase 3 · recruiting
Other Tang-Du Hospital trials
Trials by the same sponsor.
- NCT07528235 — An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intraven · Phase 1 · not yet recruiting
- NCT07516522 — Intra-arterial Methylprednisolone After Endovascular Thrombectomy · Phase 2 · recruiting
- NCT07354061 — Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) · Phase 1, PHASE2 · recruiting
- NCT07327736 — Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT · NA · not yet recruiting
- NCT07452601 — Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05067348 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tang-Du Hospital
- Last refreshed: 1 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05067348.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing